HRH3 and schizophrenia: Although, inconsistent findings on animal models mimicking schizophrenia does not bring any full proof evidence for antipsychotic properties of H3R antagonists, their waking and pro-cognitive properties uphold their therapeutic interest and can be exploited to adequately address the cognitive impairment central to schizophrenic patients which is resistant to current neuroleptics in hand, hence better clinical outcome.